Literature DB >> 28917266

Urinary biomarkers in prostate cancer detection and monitoring progression.

Duojia Wu1, Jie Ni1, Julia Beretov2, Paul Cozzi3, Mark Willcox4, Valerie Wasinger5, Bradley Walsh6, Peter Graham1, Yong Li7.   

Abstract

Prostate cancer (CaP) is the most common cancer in men and the second leading cause of cancer deaths in males in Australia. Although serum prostate-specific antigen (PSA) has been the most widely used biomarker in CaP detection for decades, PSA screening has limitations such as low specificity and potential association with over-diagnosis. Current biomarkers used in the clinic are not useful for the early detection of CaP, or monitoring its progression, and have limited value in predicting response to treatment. Urine is an ideal body fluid for the detection of protein markers of CaP and is emerging as a potential source for biomarker discovery. Gene-based biomarkers in urine such as prostate cancer antigen-3 (PCA3), and genes for transmembrane protease serine-2 (TMPRSS2), and glutathione S-transferase P (GSTP1) have been developed and evaluated in the past decades. Among these biomarkers, urinary PCA3 is the only one approved by the FDA in the USA for clinical use. The study of urine microRNAs (miRNAs) is another burgeoning area for investigating biomarkers to achieve a pre-biopsy prediction of CaP to contribute to early detection. The development of mass spectrometry (MS)-based proteomic techniques has sparked new searches for novel protein markers for many diseases including CaP. Urinary biomarkers for CaP represent a promising alternative or an addition to traditional biomarkers. Future success in biomarker discovery will rely on collaboration between clinics and laboratories. In addition, research efforts need to be moved from biomarker discovery to validation in a large cohort or separate population of patients and translation of these findings to clinical practice. In this review, we discuss urine as a potential source for CaP biomarker discovery, summarise important genetic urine biomarkers in CaP and focus on MS-based proteomic approaches as well as other recent developments in quantitative techniques for CaP urine biomarker discovery.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarker; Diagnosis; Prognosis; Prostate cancer; Proteomics

Mesh:

Substances:

Year:  2017        PMID: 28917266     DOI: 10.1016/j.critrevonc.2017.08.002

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  20 in total

Review 1.  [Urinary marker-old wine in new bottles?]

Authors:  K Fischer
Journal:  Urologe A       Date:  2018-09       Impact factor: 0.639

2.  Urinary microRNA and mRNA in Tumors.

Authors:  Erika Bandini
Journal:  Methods Mol Biol       Date:  2021

3.  Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Julia Wade; Sian Noble; Kirsty Garfield; Grace Young; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Jane Blazeby; Richard Bryant; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Vincent Gnanapragasam; Owen Hughes; Roger Kockelbergh; Howard Kynaston; Alan Paul; Edgar Paez; Philip Powell; Stephen Prescott; Derek Rosario; Edward Rowe; David Neal
Journal:  Health Technol Assess       Date:  2020-08       Impact factor: 4.014

Review 4.  Clinical implementation and current advancement of blood liquid biopsy in cancer.

Authors:  Kazunori Watanabe; Yusuke Nakamura; Siew-Kee Low
Journal:  J Hum Genet       Date:  2021-06-04       Impact factor: 3.172

Review 5.  Approaches to the discovery of non-invasive urinary biomarkers of prostate cancer.

Authors:  Andrej Jedinak; Kevin R Loughlin; Marsha A Moses
Journal:  Oncotarget       Date:  2018-08-21

Review 6.  Urinary markers aiding in the detection and risk stratification of prostate cancer.

Authors:  Nicholas Raja; Christopher M Russell; Arvin K George
Journal:  Transl Androl Urol       Date:  2018-09

Review 7.  Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers.

Authors:  Nuria Gómez-Cebrián; Ayelén Rojas-Benedicto; Arturo Albors-Vaquer; José Antonio López-Guerrero; Antonio Pineda-Lucena; Leonor Puchades-Carrasco
Journal:  Metabolites       Date:  2019-03-08

8.  Advances in Biomarkers for PCa Diagnostics and Prognostics-A Way towards Personalized Medicine.

Authors:  Carsten Stephan; Klaus Jung
Journal:  Int J Mol Sci       Date:  2017-10-20       Impact factor: 5.923

9.  Novel Synthesis of Core-Shell Silica Nanoparticles for the Capture of Low Molecular Weight Proteins and Peptides.

Authors:  Sergio G Hernandez-Leon; Jose Andre-I Sarabia-Sainz; Gabriela Ramos-Clamont Montfort; Ana M Guzman-Partida; Maria Del Refugio Robles-Burgueño; Luz Vazquez-Moreno
Journal:  Molecules       Date:  2017-10-12       Impact factor: 4.411

10.  A seven-lncRNA signature for predicting Ewing's sarcoma.

Authors:  Zhihui Chen; Xinyu Wang; Guozhu Wang; Bin Xiao; Zhe Ma; Hongliang Huo; Weiwei Li
Journal:  PeerJ       Date:  2021-06-17       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.